| scholarly article | Q13442814 |
| P50 | author | Ronald P DeMatteo | Q89998373 |
| P2093 | author name string | Mithat Gonen | |
| Binsheng Zhao | |||
| Stephen B Solomon | |||
| Peter J Allen | |||
| Ghassan K Abou-Alfa | |||
| Michael I D'Angelica | |||
| William R Jarnagin | |||
| Anne M Covey | |||
| Constantinos T Sofocleous | |||
| Lawrence H Schwartz | |||
| George I Getrajdman | |||
| Karen T Brown | |||
| Lynn A Brody | |||
| Joseph P Erinjeri | |||
| Richard K Do | |||
| Alessandra R Garcia | |||
| Gerald P O'Neill | |||
| Christopher Beattie | |||
| Kristian N Johnson | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study | Q33631372 | ||
| Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy | Q34143449 | ||
| Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. | Q34581507 | ||
| Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. | Q34714683 | ||
| The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma | Q35648702 | ||
| Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. | Q35731141 | ||
| A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma | Q36747407 | ||
| Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 | ||
| Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma | Q39420849 | ||
| Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma | Q39926325 | ||
| Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. | Q39945978 | ||
| Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results | Q46083133 | ||
| Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients | Q46902655 | ||
| Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results | Q47709482 | ||
| A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. | Q50956760 | ||
| Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial | Q58236593 | ||
| Drug-eluting Beads for Liver Embolization: Concentration of Doxorubicin in Tissue and in Beads in a Pig Model | Q61913740 | ||
| Uterine artery embolization: a treatment option for symptomatic fibroids in postmenopausal women | Q80006739 | ||
| Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies | Q82732610 | ||
| Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) | Q83157920 | ||
| Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria | Q84135417 | ||
| Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants | Q84441118 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microsphere | Q1759020 |
| hepatocellular carcinoma | Q1148337 | ||
| Hepatic artery embolization | Q22908877 | ||
| P304 | page(s) | 2046-2053 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone | |
| P478 | volume | 34 |
| Q92797759 | A global view of hepatocellular carcinoma: trends, risk, prevention and management |
| Q47107783 | A20 enhances the radiosensitivity of hepatocellular carcinoma cells to 60Co-γ ionizing radiation |
| Q39319921 | Adjuvant Medications That Improve Survival after Locoregional Therapy. |
| Q38848537 | Advanced Hepatocellular Cancer: the Current State of Future Research |
| Q92103963 | Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review |
| Q47136271 | Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation |
| Q89769433 | Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition) |
| Q28077829 | Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition |
| Q89791281 | Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis |
| Q42362049 | Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trial |
| Q92534091 | Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis |
| Q30245396 | Comparison of hepatocellular carcinoma in Eastern versus Western populations. |
| Q89474973 | Computed tomography and histopathological findings after embolization with inherently radiopaque 40μm-microspheres, standard 40μm-microspheres and iodized oil in a porcine liver model |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q38671883 | Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma |
| Q57802741 | Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques |
| Q90473382 | Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study |
| Q41493235 | Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. |
| Q52618170 | Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma? |
| Q49633716 | Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. |
| Q92004116 | Endovascular Ion Exchange Chemofiltration Device Reduces Off-Target Doxorubicin Exposure in a Hepatic Intra-arterial Chemotherapy Model |
| Q33620645 | Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. |
| Q46288051 | Exosome - miR-335 as a novel therapeutic strategy in hepatocellular carcinoma |
| Q38996765 | Gene Signature Associated with Upregulation of the Wnt/β-Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization. |
| Q48539950 | Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response. |
| Q58020832 | Hepatocellular carcinoma |
| Q89127919 | Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor |
| Q96816025 | Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC) |
| Q92980108 | Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma |
| Q36338014 | In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study |
| Q92356815 | Intermediate stage hepatocellular carcinoma: a summary review |
| Q38792625 | Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation |
| Q58559604 | Interventional Oncology: Treatment of primary liver tumors and liver metastases. Part II: non-nuclear techniques |
| Q38714207 | Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma |
| Q49627939 | Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma |
| Q46800739 | Liver-directed therapy for hepatocellular carcinoma. |
| Q50100582 | Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma |
| Q96584579 | Local and Regional Therapies for Hepatocellular Carcinoma |
| Q38686790 | Locoregional and systemic therapy for hepatocellular carcinoma |
| Q54997807 | MEIS-1 level in unresectable hepatocellular carcinoma can predict the post-treatment outcomes of radiofrequency ablation. |
| Q57781146 | Management of ruptured liver segment IV hepatocellular carcinoma: is transarterial embolization (TAE) superior to chemoembolization (TACE)?-the jury is still out |
| Q28079027 | Minimally invasive image-guided therapies for hepatocellular carcinoma |
| Q38801422 | NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017 |
| Q96134073 | Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline |
| Q55438944 | Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. |
| Q38819929 | Pancreatic islet blood flow and its measurement. |
| Q51257285 | Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. |
| Q55364224 | Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. |
| Q40259741 | Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models |
| Q92808866 | Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma |
| Q93377794 | Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials |
| Q38845532 | Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma |
| Q48348464 | Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma |
| Q36369624 | Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization |
| Q90354482 | Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver |
| Q41592391 | Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. |
| Q47788877 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. |
| Q47609170 | Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma |
| Q91713442 | Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis |
| Q64077963 | Survival benefit of higher fraction dose delivered by three-dimensional conformal radiotherapy in hepatocellular carcinoma smaller than 10 cm in size |
| Q48138815 | Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead-A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. |
| Q64259929 | Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures |
| Q33718635 | Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma |
| Q38739497 | Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials |
| Q47880175 | Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience |
| Q59515914 | Treatment of hepatic metastases from medullary thyroid cancer with transarterial embolisation |
| Q38728540 | Update on Embolization Therapies for Hepatocellular Carcinoma |
| Q94463853 | Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization |
Search more.